Baidu
map

NEJM:ROCK抑制剂培养角膜内皮细胞注射用于大泡性角膜病变的治疗

2018-03-15 zhangfan MedSci原创

研究认为,ROCK抑制剂培养后角膜内皮细胞注射可显著改善大泡性角膜病变患者症状

角膜内皮细胞(CEC)紊乱,如Fuchs角膜内皮营养不良可导致角膜水化异常、角膜模糊和视力丧失,统称为大泡性角膜病。近日研究人员考察了RHO相关蛋白激酶抑制剂(ROCK)培养的CEC细胞对大泡性角膜病变的治疗效果。

本次单中心研究招募了11名大泡性角膜病变患者收集其角膜内皮细胞,进行ROCK传代培养后得到1×106个传代细胞,将这些传代细胞注射到患者病眼前房,注射后患者保持3小时以上俯卧位。研究的主要终点是角膜透明度恢复,即注射24周后,角膜中心每平方毫米CEC细胞密度超过500个。次要终点包括角膜厚度小于630μm,Landolt C眼图最佳矫正视力改善两条以上。

首次注射24周后,11名患者全部达到主要终点,其中10人角膜中心每平方毫米CEC细胞密度超过1000个,10人角膜厚度小于630μm(91%),9人Landolt C眼图最佳矫正视力改善两条以上 (82%)。

研究认为,ROCK抑制剂培养后角膜内皮细胞注射可显著改善大泡性角膜病变患者症状。

原始出处:

Shigeru Kinoshita et al. Injection of Cultured Cells with a ROCK Inhibitor for Bullous Keratopathy. N Engl J Med. March 15, 2018.

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1976944, encodeId=dcaf19e694497, content=<a href='/topic/show?id=b9f11560065' target=_blank style='color:#2F92EE;'>#ROC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15600, encryptionId=b9f11560065, topicName=ROC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d590125, createdName=linlin2312, createdTime=Thu May 17 13:38:00 CST 2018, time=2018-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1710524, encodeId=c8211e1052483, content=<a href='/topic/show?id=750115604e7' target=_blank style='color:#2F92EE;'>#ROCK#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=146, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15604, encryptionId=750115604e7, topicName=ROCK)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a19831855420, createdName=12498dabm87暂无昵称, createdTime=Sun Aug 26 18:38:00 CST 2018, time=2018-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1851665, encodeId=9f8f1851665eb, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Mon Nov 12 02:38:00 CST 2018, time=2018-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1349124, encodeId=eb1e1349124ae, content=<a href='/topic/show?id=4337909284a' target=_blank style='color:#2F92EE;'>#角膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90928, encryptionId=4337909284a, topicName=角膜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=568152, createdName=snowpeakxu, createdTime=Sat Mar 17 00:38:00 CST 2018, time=2018-03-17, status=1, ipAttribution=)]
    2018-05-17 linlin2312
  2. [GetPortalCommentsPageByObjectIdResponse(id=1976944, encodeId=dcaf19e694497, content=<a href='/topic/show?id=b9f11560065' target=_blank style='color:#2F92EE;'>#ROC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15600, encryptionId=b9f11560065, topicName=ROC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d590125, createdName=linlin2312, createdTime=Thu May 17 13:38:00 CST 2018, time=2018-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1710524, encodeId=c8211e1052483, content=<a href='/topic/show?id=750115604e7' target=_blank style='color:#2F92EE;'>#ROCK#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=146, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15604, encryptionId=750115604e7, topicName=ROCK)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a19831855420, createdName=12498dabm87暂无昵称, createdTime=Sun Aug 26 18:38:00 CST 2018, time=2018-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1851665, encodeId=9f8f1851665eb, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Mon Nov 12 02:38:00 CST 2018, time=2018-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1349124, encodeId=eb1e1349124ae, content=<a href='/topic/show?id=4337909284a' target=_blank style='color:#2F92EE;'>#角膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90928, encryptionId=4337909284a, topicName=角膜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=568152, createdName=snowpeakxu, createdTime=Sat Mar 17 00:38:00 CST 2018, time=2018-03-17, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1976944, encodeId=dcaf19e694497, content=<a href='/topic/show?id=b9f11560065' target=_blank style='color:#2F92EE;'>#ROC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15600, encryptionId=b9f11560065, topicName=ROC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d590125, createdName=linlin2312, createdTime=Thu May 17 13:38:00 CST 2018, time=2018-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1710524, encodeId=c8211e1052483, content=<a href='/topic/show?id=750115604e7' target=_blank style='color:#2F92EE;'>#ROCK#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=146, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15604, encryptionId=750115604e7, topicName=ROCK)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a19831855420, createdName=12498dabm87暂无昵称, createdTime=Sun Aug 26 18:38:00 CST 2018, time=2018-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1851665, encodeId=9f8f1851665eb, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Mon Nov 12 02:38:00 CST 2018, time=2018-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1349124, encodeId=eb1e1349124ae, content=<a href='/topic/show?id=4337909284a' target=_blank style='color:#2F92EE;'>#角膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90928, encryptionId=4337909284a, topicName=角膜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=568152, createdName=snowpeakxu, createdTime=Sat Mar 17 00:38:00 CST 2018, time=2018-03-17, status=1, ipAttribution=)]
    2018-11-12 jklm09
  4. [GetPortalCommentsPageByObjectIdResponse(id=1976944, encodeId=dcaf19e694497, content=<a href='/topic/show?id=b9f11560065' target=_blank style='color:#2F92EE;'>#ROC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15600, encryptionId=b9f11560065, topicName=ROC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d590125, createdName=linlin2312, createdTime=Thu May 17 13:38:00 CST 2018, time=2018-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1710524, encodeId=c8211e1052483, content=<a href='/topic/show?id=750115604e7' target=_blank style='color:#2F92EE;'>#ROCK#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=146, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15604, encryptionId=750115604e7, topicName=ROCK)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a19831855420, createdName=12498dabm87暂无昵称, createdTime=Sun Aug 26 18:38:00 CST 2018, time=2018-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1851665, encodeId=9f8f1851665eb, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Mon Nov 12 02:38:00 CST 2018, time=2018-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1349124, encodeId=eb1e1349124ae, content=<a href='/topic/show?id=4337909284a' target=_blank style='color:#2F92EE;'>#角膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90928, encryptionId=4337909284a, topicName=角膜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=568152, createdName=snowpeakxu, createdTime=Sat Mar 17 00:38:00 CST 2018, time=2018-03-17, status=1, ipAttribution=)]
Baidu
map
Baidu
map
Baidu
map